Volume 63, Issue 3, Pages (March 2003)

Slides:



Advertisements
Similar presentations
Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.
Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.
A.M. Thompson, T.G. Pickering  Kidney International 
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz 
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
End-stage renal disease in developing countries
Volume 83, Issue 3, Pages (March 2013)
Stem cells for kidney repair: useful tool for acute renal failure?
Volume 63, Issue 6, Pages (June 2003)
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients  Demetrios J. Kutsogiannis, R.T.Noel.
Kidney transplantation in a low-resource setting: Nigeria experience
Volume 61, Issue 2, Pages (February 2002)
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Sabina Kersting, Leo F. Verdonck 
Burden of chronic kidney disease: North Africa
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Francesco Paolo Schena  Kidney International 
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Volume 70, Pages S21-S25 (December 2006)
Steven J. Chadban, Natalie D. Staplin  Kidney International 
End-stage renal disease in living kidney donors
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Comorbidity and confounding in end-stage renal disease
Volume 63, Issue 2, Pages (February 2003)
Volume 64, Issue 1, Pages (July 2003)
Volume 70, Issue 11, Pages (December 2006)
High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin.
Alect2 amyloidosis: primum non nocere (first, do no harm)
Acute myocardial infarction in patients with end-stage renal disease
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Fructose intake as a risk factor for kidney stone disease
Response to ‘Hepcidin levels in patients with renal disease’
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Elevated risk of stroke among patients with end-stage renal disease
Atrial fibrillation in end-stage renal disease: an emerging problem
Counteracting progression of renal disease: A look into the future
The global challenge of chronic kidney disease
V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen 
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 81, Issue 9, Pages (May 2012)
Volume 71, Issue 12, Pages (June 2007)
Prehypertension: is it relevant for nephrologists?
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Volume 54, Issue 2, Pages (August 1998)
Proteinuria in obstructive sleep apnea
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
Peritoneal dialysis in Mexico
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Organ transplantation goes to the movies
Low triiodothyronine and survival in end-stage renal disease
The Iranian model of living renal transplantation
Treatment of the primary hyperoxalurias: A new chapter
Is complement a target for therapy in renal disease?
Volume 83, Issue 3, Pages (March 2013)
Volume 70, Issue 5, Pages (September 2006)
Volume 75, Issue 7, Pages (April 2009)
Volume 70, Issue 10, Pages (November 2006)
Familial phenotype differences in PKD11
Prediction in idiopathic membranous nephropathy
Ronen Levi, Justin Silver  Kidney International 
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.
Volume 60, Issue 1, Pages (July 2001)
Presentation transcript:

Volume 63, Issue 3, Pages 1051-1057 (March 2003) High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease  Liam F. Casserly, Amit Fadia, Vaishali Sanchorawala, David C. Seldin, Daniel G. Wright, Martha Skinner, Laura M. Dember  Kidney International  Volume 63, Issue 3, Pages 1051-1057 (March 2003) DOI: 10.1046/j.1523-1755.2003.00813.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Survival from time of treatment of end-stage renal disease (ESRD) patients compared with non-ESRD patients (P = 0.1 by log-rank test). Kidney International 2003 63, 1051-1057DOI: (10.1046/j.1523-1755.2003.00813.x) Copyright © 2003 International Society of Nephrology Terms and Conditions